Short-term efficacy and safety of oral and nasal corticosteroids in covid-19 patients with olfactory dysfunction: A European multicenter study
| Autor: | Giovanni Salzano, Philippe Boelpaep, Serge-D Le Bon, Jerome R. Lechien, Luigi Angelo Vaira, Mohamad Khalife, Giacomo De Riu, Giovanna Deiana, Carlos M. Chiesa-Estomba, Mihaela Horoi, Sven Saussez, Stéphane Hans, Marzia Petrocelli, Claire Hopkins |
|---|---|
| Přispěvatelé: | Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Anosmia [SDV]Life Sciences [q-bio] Article law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine Immunology and Allergy Medicine In patient 030223 otorhinolaryngology Molecular Biology General Immunology and Microbiology business.industry SARS-CoV-2 COVID-19 anosmia olfactory smell treatment Généralités Parosmia 3. Good health Smell Treatment Infectious Diseases Multicenter study 030220 oncology & carcinogenesis medicine.symptom business After treatment Olfactory |
| Zdroj: | Pathogens Pathogens, MDPI, 2021, 10 (6), ⟨10.3390/pathogens10060698⟩ Pathogens, Vol 10, Iss 698, p 698 (2021) Pathogens, 10 (6 Pathogens; Volume 10; Issue 6; Pages: 698 |
| ISSN: | 2076-0817 |
| Popis: | Background: The objective of this study was to investigate the efficacy and safety of early administration of oral corticosteroids (OC) or nasal corticosteroids (NC) as an add-on to olfactory training (OT) versus OT alone in patients with olfactory dysfunction (OD) related to coronavirus disease 2019 (COVID-19). Methods: Patients with a positive diagnosis of COVID-19 and OD were prospectively recruited from March 22 to December 15, 2020 from 4 European hospitals. Patients had confirmed OD on psychophysical testing. All patients undertook OT, with add-on 10 days of OC (group 1: OC + OT), or 1 month of NC (group 2: NC + OT) or olfactory training alone (group 3: OT). Olfactory evaluations (Sniffin’Sticks tests) were carried out at the time of inclusion, 1 and 2 months after the start of the therapeutic course. Results: A total of 152 hyposmic or anosmic patients completed the study. Group 1, 2 and 3 included 59, 22 and 71 patients, respectively and all patient groups were comparable regarding baseline Sniffin’Sticks tests. The median Sniffin’Sticks test values significantly improved from pre-to post-intervention in all groups. The increase of Sniffin’Sticks test values was higher in group 1 (OC + OT) compared with groups 2 and 3 (p < 0.001) at one month after treatment but did not remain so at 2 months. Groups 1, 2 and 3, respectively, presented parosmia in 20/71 (28.2%), 9/22 (40.9%) and 42/71 (59.2%) patients. This difference was statistically significant between group 1 and 3 (p < 0.001). There were no patients with a worsening of the disease or an increase of the severity of the COVID-19 symptoms. Conclusions: The use of OCs in patients with OD related to mild COVID-19 is generally well-tolerated without any case of deterioration of symptoms. OC is associated with greater improvement in psychophysical olfactory evaluations at 1-month post-treatment but there was no difference at 2 months. Parosmia may be reduced following treatment with OC and NC. On the basis of these preliminary results, it is possible to state that considering the 2 months efficacy of OC and NC with respect to the OT alone and the risk-benefit ratio, the benefit to start a specific treatment of COVID-19 related OD cannot be demonstrated and there is a need for a randomised controlled trial to assess this further. SCOPUS: ar.j info:eu-repo/semantics/published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|